- Home
- LFVN vs BDTX Comparison
LFVN vs BDTX Comparison
Compare LFVN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.2M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LFVN | BDTX |
|---|---|---|
| Price | $6.32 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 186.0K | ★ 959.4K |
| Earning Date | 02-04-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ 143.91 | N/A |
| EPS | ★ 0.78 | 0.38 |
| Revenue | ★ $228,877,000.00 | $70,000,000.00 |
| Revenue This Year | $1.54 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $8.13 | ★ $6.77 |
| Revenue Growth | ★ 16.77 | N/A |
| 52 Week Low | $5.69 | $1.20 |
| 52 Week High | $25.89 | $4.94 |
Technical Indicators
Market Signals| Indicator | LFVN | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 39.90 |
| Support Level | $6.03 | $2.56 |
| Resistance Level | $6.84 | $2.83 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 41.67 | 32.98 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.